keyword
MENU ▼
Read by QxMD icon Read
search

Guideline for hepatocellular carcinoma

keyword
https://www.readbyqxmd.com/read/29234639/hepatocellular-carcinoma-with-macrovascular-invasion-defining-the-optimal-treatment-strategy
#1
REVIEW
Charlotte E Costentin, Cristina R Ferrone, Ronald S Arellano, Suvranu Ganguli, Theodore S Hong, Andrew X Zhu
Background: Tumoral macrovascular invasion (MVI) of hepatic and/or portal vein branches is a common phenomenon in hepatocellular carcinoma (HCC) and is associated with poorer prognosis when compared to HCC without MVI. Summary: Current international guidelines for the management of HCC recommend sorafenib as the only treatment option in case of MVI. Despite guideline recommendations, several alternative options have been tested to manage HCC with MVI: surgery, transarterial chemoembolization, external or internal radiation, hepatic arterial infusion chemotherapy, percutaneous treatment, cryotherapy, or the combination of two or more of these strategies, with or without sorafenib...
November 2017: Liver Cancer
https://www.readbyqxmd.com/read/29207969/pre-treatment-alphafeto-protein-in-hepatocellular-carcinoma-with-non-viral-aetiology-a-prospective-study
#2
Siriwardana Rohan Chaminda, Thilakarathne Suchintha, Niriella Madunil Anuk, Dassanayake Anuradha Supun, Gunathilake Mahen Bhagya, Liyanage Chandika Anuruddha Habarakada, De Silva Hithadurage Janaka
BACKGROUND: Alpha-fetoprotein (AFP) is a biomarker for hepatocellular carcinoma (HCC). The significance of pre-treatment AFP (pt-AFP) in non-viral HCC (nvHCC) is not clear. METHODS: Patients with nvHCC, referred to a Hepatobiliary Clinic from September 2011-2015 were screened. HCC was diagnosed using American Association for the Study of Liver Disease guidelines, and TNM staged. nvHCC was diagnosed when HBsAg and anti-HCVAb was negative. Child-Turcotte-Pugh (CTP) and Model for End-stage Liver Disease (MELD) scores were calculated...
December 6, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/29201774/hepatitis-action-plan-and-changing-trend-of-liver-disease-in-japan-viral-hepatitis-and-nonalcoholic-fatty-liver-disease
#3
REVIEW
Tatsuya Kanto, Sachiyo Yoshio
In Japan, the estimated number of chronic hepatitis B virus infections was 1.1 to 1.4 million, and that of chronic hepatitis C virus was 1.9 to 2.3 million in 2000. The mortality of hepatocellular carcinoma had been increasing and hit the peak at around 2002, which subsequently started to decrease. Japan has a national action plan for addressing viral hepatitis called Basic Act on Hepatitis Measures, established in 2009. In 2011, basic guidelines for promotion of control measures for hepatitis were issued, comprising nine principles in order to promote measures to prevent hepatitis B and C...
January 2017: Euroasian journal of hepato-gastroenterology
https://www.readbyqxmd.com/read/29195677/do-smoking-and-alcohol-behaviours-influence-gi-cancer-survival
#4
REVIEW
Úna C McMenamin, Stephen McCain, Andrew T Kunzmann
Little is known about the role of alcohol and smoking in GI cancer survival compared to GI cancer development. We systematically reviewed the evidence for a role of smoking and alcohol in prognosis among GI cancer patients and inform whether smoking or alcohol cessation interventions or guidelines for GI cancer patients are likely to improve prognosis. A total of 84 relevant studies were identified. Continued smokers, particularly heavy smokers, had worse prognosis than never smokers in most GI cancers. However, more evidence is needed to establish the likely impact of smoking cessation interventions amongst GI cancer patients...
October 2017: Best Practice & Research. Clinical Gastroenterology
https://www.readbyqxmd.com/read/29190996/surgical-resection-for-hepatocellular-carcinoma-with-portal-vein-tumor-thrombus-in-the-asia-pacific-region-beyond-the-barcelona-clinic-liver-cancer-treatment-algorithms-a-review-and-update
#5
REVIEW
Jia-Zhou Ye, Yan-Yan Wang, Tao Bai, Jie Chen, Bang-De Xiang, Fei-Xiang Wu, Le-Qun Li
Portal vein tumor thrombus (PVTT) usually worsens prognosis of hepatocellular carcinoma (HCC), as characterized by aggressive disease progression, impaired liver function and tolerance to treatment. Conventionally, the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) accepted the Barcelona Clinical Liver Cancer (BCLC) treatment algorithms, identifying PVTT as an absolute contra-indication of surgical resection for HCC. HCC-PVTT patients are offered sorafenib as the standard treatment...
November 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29185250/management-of-hepatitis-c-in-decentralised-versus-centralised-drug-substitution-programmes-and-minimally-invasive-point-of-care-tests-to-close-gaps-in-the-hcv-cascade
#6
Andrea Bregenzer, Anna Conen, Jürg Knuchel, Andrée Friedl, Franz Eigenmann, Martin Näf, Peter Ackle, Martin Roth, Christoph Andreas Fux
BACKGROUND: In Switzerland, intravenous drug use accounts for the majority of hepatitis C virus (HCV) infections. Early HCV treatment prevents further transmissions and reduces morbidity and mortality due to decompensated liver cirrhosis and hepatocellular carcinoma. Nevertheless, patients in drug substitution programmes are often insufficiently screened and treated. AIM: The aim was to compare the current state of HCV management in centralised and decentralised drug substitution programmes of the canton Aargau...
November 29, 2017: Swiss Medical Weekly
https://www.readbyqxmd.com/read/29181069/sorafenib-combined-with-hepatectomy-in-patients-with-intermediate-stage-and-advanced-hepatocellular-carcinoma
#7
Lei Zhuang, Tianfu Wen, Mingqing Xu, Jiayin Yang, Wentao Wang, Hong Wu, Yong Zeng, Lvnan Yan, Yonggang Wei, Bo Li
Introduction: Guidelines based on the Barcelona Clinic Liver Cancer (BCLC) classification system recommend that hepatic resection should be performed only in patients in BCLC stage A. Patients with stage B or stage C should receive palliative or no treatment. However, actual clinical practice varies, and a recent analysis of hepatocellular carcinoma (HCC) surgery outcomes in high volume surgical centers throughout the world concluded that hepatectomy can provide survival benefit for selected patients in all three BCLC stages...
October 2017: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/29172395/the-clinicopathological-and-prognostic-significance-of-the-gross-classification-of-hepatocellular-carcinoma
#8
Yangkyu Lee, Hyunjin Park, Hyejung Lee, Jai Young Cho, Yoo-Seok Yoon, Young-Rok Choi, Ho-Seong Han, Eun Sun Jang, Jin-Wook Kim, Sook-Hyang Jeong, Soomin Ahn, Haeryoung Kim
Background: We aimed to determine the clinicopathological significance of the gross classification of hepatocellular carcinoma (HCC) according to the Korean Liver Cancer Association (KLCA) guidelines. Method: A retrospective analysis was performed on 242 cases of consecutively resected solitary primary HCC between 2003 and 2012 at Seoul National University Bundang Hospital. The gross classification [vaguely nodular (VN), expanding nodular (EN), multinodular confluent (MC), nodular with perinodular extension (NP) and infiltrative (INF)] was reviewed for all cases, and were correlated with various clinicopathological features and the expression status of "stemness"-related (CK19, EpCAM) and epithelial-mesenchymal transition (EMT)-related (uPAR, Ezrin) markers...
November 24, 2017: Journal of Pathology and Translational Medicine
https://www.readbyqxmd.com/read/29123005/percutaneous-ablation-for-hepatocellular-carcinoma-and-peritoneal-dialysis
#9
Annabel Boyer, Marc-Antoine Jegonday, Antoine Lanot, Maxence Ficheux, Thierry Lobbedez, Clémence Bechade
Hepatocellular carcinoma (HCC) is the second leading cause of death by cancer worldwide. Resection and liver transplantation are the gold standards, but only a minority of people are eligible. Percutaneous ablation therapies, such as microwave ablation (MWA), have consequently been developed. There is a lack of guidelines regarding the treatment of HCCs in end-stage renal disease (ESRD) patients. Here, we report the case of a 67-year-old patient who was undergoing peritoneal dialysis (PD) for chronic congestive heart failure and who presented with an HCC while undergoing PD...
November 2017: Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
https://www.readbyqxmd.com/read/29108191/-an-interpretation-of-the-aasld-practice-guideline-on-the-diagnosis-and-management-of-nonalcoholic-fatty-liver-disease-in-2017
#10
Y M Nan, N Fu, W C Li, L L Kong, X W Yuan, S Y Zhang, L D Liu, Y Lu, L Y Cui
The American Association for the Study of Liver Diseases (AASLD) updated and published the Practice Guidance for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease (NAFLD) in July 2017, which provides recommendations for the accurate diagnosis, treatment, and effective prevention of NAFLD. Related metabolic diseases should be considered during the initial evaluation of patients suspected of NAFLD. Noninvasive diagnostic techniques including transient elastography, magnetic resonance elastography, and serum biochemical models should be used to evaluate the development and progression of liver fibrosis in patients with NAFLD...
September 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29101980/acr-appropriateness-criteria-%C3%A2-chronic-liver%C3%A2-disease
#11
Jeanne M Horowitz, Ihab R Kamel, Hina Arif-Tiwari, Sumeet K Asrani, Nicole M Hindman, Harmeet Kaur, Michelle M McNamara, Richard B Noto, Aliya Qayyum, Tasneem Lalani
Because liver fibrosis can be treated, it is important to diagnose liver fibrosis noninvasively and monitor response to treatment. Although ultrasound (grayscale and Doppler) can diagnose cirrhosis, it does so unreliably using morphologic and sonographic features and cannot diagnose the earlier, treatable stages of hepatic fibrosis. Transient elastography, ultrasound elastography with acoustic radiation force impulse, and MR elastography are modalities that can assess for hepatic fibrosis. Although all international organizations recommend ultrasound for screening for hepatocellular carcinoma, ultrasound is particularly limited for identifying hepatocellular carcinoma in patients with obesity, nonalcoholic fatty liver disease, and nodular cirrhotic livers...
November 2017: Journal of the American College of Radiology: JACR
https://www.readbyqxmd.com/read/29096967/hepatocellular-carcinoma-present-and-future
#12
REVIEW
Carolina Armengol, Maria Rosa Sarrias, Margarita Sala
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with over 740,000 new cases per year and the third leading cause of cancer-related death, with a growing incidence in recent years. This tumor usually arises in patients with an underlying chronic liver disease. The management of this tumor has improved over the past 2 decades: patients at risk are included in a surveillance program, a prognostic staging system has been created and, finally, new treatments particularly aimed at patients with advanced HCC have been developed...
October 30, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/29080006/local-arterial-therapies-in-the-management-of-unresectable-hepatocellular-carcinoma
#13
REVIEW
Samdeep K Mouli, Laura W Goff
Most patients with hepatocellular carcinoma present with intermediate to advanced disease, where curative therapies are no longer an option. These patients with intermediate to advanced disease represent a heterogeneous population with regard to tumor burden, liver function, and performance status. While the Barcelona Clinic Liver Cancer (BCLC) staging system offers guidelines for the management of these patients, strict adherence to these guidelines may limit treatment options for these patients. Several locoregional therapies exist for these patients, including conventional transarterial chemoembolization (cTACE), transarterial embolization (TAE), drug-eluting embolization (DEE), and radioembolization...
October 27, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29074347/management-consensus-guideline-for-hepatocellular-carcinoma-2016-updated-by-the-taiwan-liver-cancer-association-and-the-gastroenterological-society-of-taiwan
#14
(no author information available yet)
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality in Taiwan. To help clinical physicians to manage patients with HCC, the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan produced the management consensus guideline for HCC. METHODS: The recommendations focus on nine important issues on management of HCC, including surveillance, diagnosis, staging, surgery, local ablation, transarterial chemoembolization/transarterial radioembolization/hepatic arterial infusion chemotherapy, systemic therapy, radiotherapy, and prevention...
October 23, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/29066853/non-invasive-quantitative-imaging-of-hepatocellular-carcinoma-growth-in-mice-by-micro-ct-using-liver-targeted-iodinated-nano-emulsions
#15
Nicolas Anton, Alexandru Parlog, Ghina Bou About, Mohamed F Attia, Marie Wattenhofer-Donzé, Hugues Jacobs, Isabelle Goncalves, Eric Robinet, Tania Sorg, Thierry F Vandamme
Hepatocellular carcinoma (HCC) is the only cancer for which non-invasive diagnosis is recognized by international guidelines. Contrast agent free ultrasound imaging, computed tomography (CT) and/or magnetic resonance imaging are techniques used for early detection and confirmation. Clinical evidence depicts that CT is 30% less precise as compared to MRI for detection of small tumors. In our work, we have reported some novel tools that can enhance the sensitivity and precision of CT applied to preclinical research (micro-CT)...
October 24, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29052791/potential-diagnostic-performance-of-contrast-enhanced-ultrasound-and-tumor-markers-in-differentiating-combined-hepatocellular-cholangiocarcinoma-from-hepatocellular-carcinoma-and-cholangiocarcinoma
#16
Xiao-Wen Huang, Yang Huang, Li-da Chen, Zhu Wang, Zheng Yang, Jin-Ya Liu, Xiao-Yan Xie, Ming-De Lu, Shun-Li Shen, Wei Wang
PURPOSE: To evaluate the diagnostic performance of the combination of tumor markers [alpha-fetoprotein (AFP) and carbohydrate antigen 19-9 (CA19-9)] and imaging features in differentiating combined hepatocellular-cholangiocarcinoma (CHC) from hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). METHODS: Forty consecutive patients with pathologically proven CHC were retrospectively evaluated with contrast-enhanced ultrasound (CEUS). Additionally, 40 HCC and 40 CC patients who were randomly selected from the same period served as a control group...
October 20, 2017: Journal of Medical Ultrasonics
https://www.readbyqxmd.com/read/28989699/the-status-of-transarterial-chemoembolization-treatment-in-the-era-of-precision-oncology
#17
REVIEW
Valerie Fako, Xin Wei Wang
Transarterial chemoembolization (TACE) is the gold standard of therapy for patients with unresectable intermediate stage hepatocellular carcinoma (HCC), and is also commonly used as postresection adjuvant therapy in Asia. The delivery of TACE is highly variable from center to center, and clinical decision making for patients is based primarily on tumor staging guidelines, with very little focus on individualized tumor features. This review will discuss recent efforts for improving patient outcomes with TACE treatment through personalized medicine advances, including ongoing clinical trials investigating the combination of targeted therapy with TACE and the discovery of prognostic biomarkers for predicting TACE response...
April 2017: Hepatic Oncology
https://www.readbyqxmd.com/read/28989095/risk-factors-and-prevention-of-hepatocellular-carcinoma-in-the-era-of-precision-medicine
#18
REVIEW
Naoto Fujiwara, Scott L Friedman, Nicolas Goossens, Yujin Hoshida
Chronic fibrotic liver disease caused by viral or metabolic etiologies is a high-risk condition for developing hepatocellular carcinoma (HCC). Even after complete HCC tumor resection or ablation, the carcinogenic tissue microenvironment in the remnant liver can give rise to recurrent de novo HCC tumors, which progress into incurable, advanced-stage disease in the majority of patients. Thus, early detection and prevention of HCC development is, in principle, the most impactful strategy to improve patient prognosis...
October 5, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28989094/impact-of-time-to-surgery-in-the-outcome-of-patients-with-liver-resection-for-bclc-0-a-stage-hepatocellular-carcinoma
#19
Chetana Lim, Prashant Bhangui, Chady Salloum, Concepción Gómez-Gavara, Eylon Lahat, Alain Luciani, Philippe Compagnon, Julien Calderaro, Cyrille Feray, Daniel Azoulay
BACKGROUND & AIMS: The Barcelona Clinic Liver Cancer (BCLC) guidelines recommend resection for very early and early single hepatocellular carcinoma (HCC) patients. It is not known whether a delay in resection from the time of diagnosis (the time to surgery [TTS], i.e. the elapsed time from diagnosis to surgery) affects outcomes. We aim to evaluate the impact of TTS on recurrence and survival outcomes in patients with HCC. METHODS: All patients resected for BCLC stage 0-A single HCC from 2006 to 2016 were studied to evaluate the impact of TTS on recurrence rate, recurrence-free survival (RFS), transplantability following recurrence, and intention-to-treat overall survival (ITT-OS)...
October 6, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28981737/management-strategies-to-minimize-mortality-in-liver-resection-for-hepatocellular-carcinoma
#20
Shintaro Yamazaki, Tadatoshi Takayama
The precise assessment of both tumor factor and the liver function is of a crucial value the surgical treatment with the greatest guarantee of hepatocellular carcinoma (HCC), as the balance between the operative procedure and the remnant liver function is the most important concern in patients with chronic liver disease. The mortality rate in liver resection has decreased significantly worldwide, according to various surgical criteria for liver resection. Among countries where HCC is prevalent Japan is a leading country in doing liver resection...
October 1, 2017: Japanese Journal of Clinical Oncology
keyword
keyword
70152
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"